ONVOORGANOVO HOLDINGS, INC.

Nasdaq organovo.com


$ 1.11 $ -0.05 (-4.35 %)    

Friday, 19-Apr-2024 15:58:03 EDT
QQQ $ 414.59 $ -8.76 (-2.07 %)
DIA $ 379.83 $ 1.96 (0.52 %)
SPY $ 494.96 $ -4.36 (-0.87 %)
TLT $ 89.15 $ 0.32 (0.36 %)
GLD $ 221.02 $ 0.69 (0.31 %)
$ 1.1
$ 1.12
$ 0.00 x 0
$ 0.00 x 0
$ 1.10 - $ 1.18
$ 0.89 - $ 2.17
275,160
na
9.58M
$ 1.56
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-08-2024 12-31-2023 10-Q
2 11-09-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 07-13-2023 03-31-2023 10-K
5 02-09-2023 12-31-2022 10-Q
6 11-10-2022 09-30-2022 10-Q
7 08-11-2022 06-30-2022 10-Q
8 06-10-2022 03-31-2022 10-K
9 02-14-2022 12-31-2021 10-Q
10 11-08-2021 09-30-2021 10-Q
11 08-06-2021 06-30-2021 10-Q
12 06-15-2021 03-31-2021 10-K
13 02-08-2021 12-31-2020 10-Q
14 11-05-2020 09-30-2020 10-Q
15 08-10-2020 06-30-2020 10-Q
16 05-28-2020 03-31-2020 10-K
17 02-10-2020 12-31-2019 10-Q
18 11-07-2019 09-30-2019 10-Q
19 08-08-2019 06-30-2019 10-Q
20 06-03-2019 03-31-2019 10-K
21 02-07-2019 12-31-2018 10-Q
22 11-08-2018 09-30-2018 10-Q
23 08-09-2018 06-30-2018 10-Q
24 05-31-2018 03-31-2018 10-K
25 02-08-2018 12-31-2017 10-Q
26 11-09-2017 09-30-2017 10-Q
27 08-09-2017 06-30-2017 10-Q
28 06-07-2017 03-31-2017 10-K
29 02-09-2017 12-31-2016 10-Q
30 11-03-2016 09-30-2016 10-Q
31 08-04-2016 06-30-2016 10-Q
32 06-09-2016 03-31-2016 10-K
33 02-08-2016 12-31-2015 10-Q
34 11-09-2015 09-30-2015 10-Q
35 08-10-2015 06-30-2015 10-Q
36 06-09-2015 03-31-2015 10-K
37 02-06-2015 12-31-2014 10-Q
38 11-07-2014 09-30-2014 10-Q
39 08-08-2014 06-30-2014 10-Q
40 06-10-2014 03-31-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-ultragenyx-pharmaceutical-shares-are-trading-lower-by-around-9-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new d...

 why-organovo-stock-is-up-today
Why Organovo Stock Is Up Today
04/15/2024 14:56:20

Organovo released the complete details of its 16-week, randomized, placebo-controlled, multi-center Phase 2 study of the non-st...

 dow-jumps-over-300-points-goldman-sachs-posts-upbeat-earnings

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday. The Dow traded up 0.8...

Core News & Articles
Market-Moving News for April 15th
04/15/2024 12:44:03

GS: 4.5% | Goldman Sachs shares are trading higher after the company reported better-than-expected Q1 EPS and revenues. LGVN: ...

 why-medical-properties-trust-shares-are-trading-higher-by-around-13-here-are-20-stocks-moving-premarket

Shares of Medical Properties Trust, Inc. (NYSE: MPW) rose sharply in today’s pre-market trading after the company announced th...

 organovo-presents-fxr314-3d-human-tissue-model-findings

The presentation highlights preclinical data characterizing the activity of FXR314 in 3D models of human Crohn's disease an...

 organovo-highlights-fxr314-combination-therapy-potential-and-plan

Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerativ...

 why-logitech-international-shares-are-trading-higher-by-over-11-here-are-20-stocks-moving-premarket

Gainers AERWINS Technologies Inc. (NASDAQ: AWIN) shares surged 91.2% to $0.2180 in pre-market trading after falling 10% on Mon...

 organovo-granted-us-patent-11789011-today-for-engineered-three-dimensional-breast-tissue-adipose-and-tumor-disease-model-background-p1-models-disclosed-herein-have-several-advantages-over-current-screening-tools

https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11789011

 stocks-that-hit-52-week-lows-on-tuesday

  On Tuesday, 164 companies achieved new lows for the year.

 stocks-that-hit-52-week-lows-on-monday

  During Monday, 102 stocks hit new 52-week lows.

 organovo-advances-clinical-timelines-for-fxr314-and-provides-updates-on-nash-phase-2-data

Organovo Holdings, Inc.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION